Sep 30 |
Travere Therapeutics Faces Challenges But Holds Promise With Filspari Beyond IgAN
|
Sep 27 |
Travere slips after pausing late-stage trial’s enrollments
|
Sep 27 |
Costco, Scholastic And 3 Stocks To Watch Heading Into Friday
|
Sep 26 |
Travere Therapeutics Announces Voluntary Pause of Enrollment in the Phase 3 HARMONY Study of Pegtibatinase Related to Commercial Manufacturing Scale-Up
|
Sep 12 |
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|
Sep 10 |
Travere Therapeutics to Present at the 2024 Cantor Global Healthcare Conference
|
Sep 6 |
Analyst Ratings For Travere Therapeutics
|
Sep 6 |
NIO To Rally Around 65%? Here Are 10 Top Analyst Forecasts For Friday
|
Sep 6 |
Travere gains on full FDA approval for kidney drug Filspari
|
Sep 5 |
Travere Therapeutics Announces Full FDA Approval of FILSPARI® (sparsentan), the Only Non-Immunosuppressive Treatment that Significantly Slows Kidney Function Decline in IgA Nephropathy
|